Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.
https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine
It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.
https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Epstein-Barr Virus Vaccine, Phase I
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1744 Views
-
Last post by Tif
-
- 1 Replies
- 428 Views
-
Last post by Leonard
-
- 3 Replies
- 498 Views
-
Last post by Leonard
-
- 2 Replies
- 1073 Views
-
Last post by DIM
-
- 0 Replies
- 1379 Views
-
Last post by Tif
-
- 0 Replies
- 1981 Views
-
Last post by Tif
-
- 0 Replies
- 1497 Views
-
Last post by Tif
-
- 1 Replies
- 1133 Views
-
Last post by 1eye
-
- 4 Replies
- 2501 Views
-
Last post by NHE